Recorded history of Melanotan II — FDA records, PCAC review history, and state overlays. Each entry links to its source; entries marked reported rest on reported sources; source classification alone does not authenticate a vote tally.
Planned review
Eligibility not established here
FDA intends to review Melanotan II at a further Pharmacy Compounding Advisory Committee meeting — by the end of February 2027 (exact date not yet posted). FDA PCAC ↗
We do not sell, source, or supply Melanotan II. This is a monitoring record from public government sources — not a product, and not advice.
Federal history
No MSR event recorded in the published federal history for Melanotan II. This is a gap in this tracker’s record, not evidence that no federal position or source exists.
State overlays
No MSR event recorded in the published state history for Melanotan II. State boards hold independent authority; legislation is monitored via LegiScan and board positions are added as they are verified.
Track Melanotan II changes
Get the free weekly Brief — FDA and state moves on peptide & GLP-1 compounding, with the source and the date. Members are alerted for their states as soon as a change is published.
